Home

Recommend Products

Special Offer

Bulk Products

New Arrivals

Hot Sales

Special Offer

Chemical Structure Cat. No. Product Name CAS No.
MK-1775 Chemical Structure
BCP01928 MK-1775 955365-80-7
MK-1775 is a potent and selective Wee1 kinase inhibitor with an IC50 of 5.2 nM.
BMS-986205 Chemical Structure
BCP20339 BMS-986205 1923833-60-6
CAL-101 Chemical Structure
BCP02532 CAL-101 870281-82-6
CAL-101 is a potent PI3K p110δ inhibitor with an IC50 of 65 nM.
Physostigmine salicylate Chemical Structure
BCP25378 Physostigmine salicylate 57-64-7
Physostigmine salicylate is a reversible cholinesterase inhibitor, a parasympathomimetic alkaloid.
GSK2330672 Chemical Structure
BCP17155 GSK2330672 1345982-69-5
GSK2330672 is a highly potent, nonabsorbable ASBT(apical sodium-dependent bile acid transporter) inhibitor (hASBT IC50=42 ± 3 nM) which lowers glucose in an animal model of type 2 diabetes and shows excellent developability properties for evaluating the potential therapeutic utility of a nonabsorbable ASBT inhibitor for treatment of patients with type 2 diabetes.
APR-246 Chemical Structure
BCP20294 APR-246 5291-32-7
APR-246, also known as PRIMA-1MET, is a quinuclidinone derivative that targets the Wrap53 gene with potential antineoplastic activity. p53 activator APR-246 binds to and activates transcription of the Wrap53 gene, which results in an increase in WRAP53 p53 antisense transcript levels and, potentially, an increase in native p53 activity; in turn, increased p53 activity may lead to an induction of cell cycle arrest and apoptosis in tumor cells. This agent may work synergistically with other antineoplastic agents.
Vistusertib Chemical Structure
BCP05748 Vistusertib 1009298-59-2
AZD2014 is a selective inhibitor of mTOR kinase.
SelenocystaMine hydrochloride Chemical Structure
BCP02640 SelenocystaMine hydrochloride 3542-13-0
FG-4592 Chemical Structure
BCP02523 FG-4592 808118-40-3
FG-4592 is an inhibitor of hypoxia inducible factor (HIF) prolyl hydroxylase currently in clinical development for the treatment of anemia.
Nicotinamide Riboside Chloride Chemical Structure
BCP20094 Nicotinamide Riboside Chloride 23111-00-4
Nicotinamide riboside is a pyridine-nucleoside form of vitamin B3 that functions as a precursor to nicotinamide adenine dinucleotide or NAD+.
Brivaracetam Chemical Structure
BCP14251 Brivaracetam 357336-20-0
Brivaracetam(UCB-34714) is a 4-substituted pyrrolidone butanamide as agent with significant antiepileptic activity; high affinity SV2A ligand and also shows an ability to inhibit Na+ channels.
NSC 133723 Chemical Structure
BCP02884 NSC 133723 19741-14-1
NSC 131463 is a dihydrofolate reductase potent inhibitor with an IC50 of 1 nM.
AZD0156 Chemical Structure
BCP18990 AZD0156 1821428-35-6
AZD0156 is an oral, potent and selective ATM kinase inhibitor, inhibiting the kinase activity of ATM and ATM-mediated signaling, preventing DNA damage checkpoint activation, and disrupting DNA damage repair, inducing tumor cell apoptosis, and leading to cell death in ATM-overexpressing tumor cells.
LOXO-195 Chemical Structure
BCP20662 LOXO-195 2097002-61-2
LOXO-195 is a next-generation TRK kinase (TKI) inhibitor, with IC50s of 0.6±0.1 nM, <2.5 nM for TRKA and TRKC respectively.
WZ4002 Chemical Structure
BCP02515 WZ4002 1213269-23-8
WZ4002 is an EGFR T790M inhibitor(IC50<20nM).
Bedaquiline Chemical Structure
BCP02829 Bedaquiline 843663-66-1
Bedaquiline, also known as TMC207 and R207910, is a diarylquinoline anti-tuberculosis drug.
Ulixertinib Chemical Structure
BCP04232 Ulixertinib 869886-67-9
Ulixertinib(BVD-523&VRT752271) is a pyrrole inhibitors of ERK protein kinase.
LY2157299 Chemical Structure
BCP02173 LY2157299 700874-72-2
LY2157299 is a novel selective small molecule transforming growth factor beta receptor (TGF-βR) kinase inhibitor with IC50 of 86 nM and 2 nM for TβR1 and 2 nM, respectively.
EAI045 Chemical Structure
BCP17698 EAI045 1942114-09-1
EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants.
Dolutegravir Chemical Structure
BCP02329 Dolutegravir 1051375-16-6
Dolutegravir is an integrase inhibitor being developed for the treatment of human immunodeficiency virus (HIV)-1 infection by GlaxoSmithKline (GSK) on behalf of Shionogi-ViiV Healthcare LLC.
12下一页共 30 条记录 1 / 2 页 
0086-13720134139